-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
READ MORE: Global, Amperco Bio, Cancer Screening, Antibody Testing San Jose, Ca., August 11, 2020 /AGENCY/ -- Ampco Biomedical Technology Co., Ltd. ("Ampco" or "We" or "Company") (NASDAQ: ANPC) today announced that it has started operating its new Philadelphia laboratory and has completed the installation of its renovation facilities and phase 1 equipment in July 2020.
phase 1 device in the laboratory is a Roche diagnostic analyzer, Cobas e411, which has been approved for emergency use by the FDA's new coronary pneumonia antibody test.
Ampereco plans to conduct cancer screening studies for cancer differentiation analysis techniques and to provide commercial new coronary pneumonia antibody testing using Roche Cobas e411 devices, which will be used once they have been identified and approved separately in accordance with FDA regulations.
since the second quarter of 2020, Ampeco San Jose Laboratory has verified the detection of new coronary pneumonia antibodies on the Roche Diagnostic Analyzer Cobas e411 machine.
verification is completed in the second half of 2020, we will complete all other regulatory approvals and will be commercially available.
, chief executive officer of Ampereco, commented, "The start-up of our Philadelphia laboratory marks a new stage of development for Ampereco in the United States.
Our important patent pool (which has so far received 19 U.S. patents), highly innovative cancer screening technologies (cancer differentiation analysis techniques) and their sample size (greater than 180,000 sample sizes), well-known healthcare partners, and our biomedical laboratories on the East and West coasts will make a significant contribution to our success in the United States.
" About Ampco Biomedical Technology Co., Ltd. Amperco Biomedical Technology Co., Ltd. is a biotechnology company dedicated to early cancer screening and testing, as of June 30, 2020, the company has a total of 128 patents.
two certified clinical laboratories in China and CLIA and CAP-accredited clinical laboratories in the United States.
is available for a range of cancer screening and testing tests, including CDA (Cancer Differentiation Analysis), Biotechnology, Immunology and Genomics.
in its latest market research report, Frost and Sullivan, as of May 2020, based on 41,700 clinical samples, Ampco ranks third in the world and first in China among companies providing next-generation early-stage cancer screening and testing technologies.
clinical samples show that Ampereco's CDA technology and platform can detect the risk of more than 20 types of cancer.
.